Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of two-dose adjuvanted H5N1 vaccine antigen levels in adults and elderly subjects
2009-012385-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in Avian Influenza (AI) (2 arms), sponsored by Novartis. Primary endpoints: Day 43 post-vaccination ratio of geometric mean titers between 3.75 microgram and 7.5 microgram groups, Immunogenicity according to CHMP criteria and 1 more. Started Jul 2009; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on 2009-012385-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012385-31.